Bioventus Inc. 8-K

What Happened

• On April 16, 2026 the U.S. Food & Drug Administration issued a final order reclassifying non‑invasive bone growth stimulators — including Bioventus’ Exogen® Ultrasound Bone Healing System — from Class III to Class II devices.
• In connection with that reclassification, the Centers for Medicare & Medicaid Services updated billing requirements and the Medicare fee schedule for non‑invasive bone growth stimulators billed under HCPCS codes E0747, E0748, and E0760 for dates of service on or after May 18, 2026.
• Bioventus filed a Current Report on Form 8‑K on May 21, 2026 and stated that, based on currently available information, it does not presently expect the reimbursement changes to have a material impact on its financial results for fiscal year 2026 and is reiterating its previously issued 2026 financial guidance.

Key Details

• FDA final order date: April 16, 2026.
• CMS billing/fee schedule effective for services on or after: May 18, 2026.
• Affected HCPCS codes: E0747, E0748, E0760.
• Company action: Reiterated 2026 financial guidance; will continue to monitor potential long‑term effects and possible future CMS actions that could require revising its outlook. Form 8‑K signed May 21, 2026 by Anthony D’Adamio (SVP & General Counsel).

Why It Matters

• FDA down‑classification from Class III to Class II may reduce regulatory burden and could affect market access for Exogen and similar devices over time.
• CMS’s updated billing rules and fee schedule determine Medicare reimbursement levels; while Bioventus currently expects no material impact to FY2026 results, changes to Medicare reimbursement are a direct driver of device revenue and profitability.
• Investors should note the company has reiterated its 2026 guidance but will monitor further CMS actions — any future reimbursement adjustments could materially affect revenue and may prompt guidance updates.